Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study

Abstract

<jats:p>Little information is available from real-life studies evaluating the efficacy of guselkumab in moderate-to-severe psoriasis. In this real-life study, we retrospectively examined a database of 52 patients with moderate-to-severe psoriasis treated with guselkumab (100 mg, s.c.) and followed for 1 year. Disease severity and treatment response was assessed by the Psoriasis Area and Severity Index (PASI) at baseline and after 4, 12, 20, 28, 36, 44, and 52 weeks. Predictors of a PASI response were evaluated by univariate and multivariate regression. After 12 months, 84.2% of patients (mean age 51.3 ± 14.1 years) treated with guselkumab achieved a PASI score of &lt;3. Furthermore, PASI score decreased from 20 ± 13.3 at baseline to 4.4 ± 4.7 and 2.7 ± 3.9 at 12 and 20 weeks, and PASI 75, 90, and 100 response was achieved in 84.2%, 78.9%, and 63.2% of patients respectively at 12 months. Stepwise multivariate regression analysis revealed that previous biological treatment and the presence of comorbidities were associated with poorer response between 28–44 weeks, however the presence of obesity per se was not associated with poorer response. Difficult-to-treat areas were also improved as early as 12 weeks following guselkumab. Guselkumab was observed to be effective and safe in patients with moderate-severe chronic psoriasis in a real world-setting.</jats:p>

Guselkumab: Mid‐term effectiveness, drug survival, and safety in real clinical practice

“…They attribute these differences to a population with different characteristics (older mean age: 60 years vs 44 years) and have had greater previous exposure to other biological treatments (4 or more), while 80% of the RCTs were bionaïve 2 . Unlike the data presented by Galluzzo, 5 a clear tendency is demonstrated for overweight or obese patients to show a lower PASI90 response rate.…”

“…The most complete series is the one provided by Galluzzo et al 5 in which they present a 52‐week follow‐up of 52 patients. The demographic characteristics of this series are similar to ours, although the percentage of naïve patients (n = 42.3%) is 4.6 times greater that of our sample.…”

Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti‐ interleukin ‐17 treatment: A real‐life 52‐week retrospective study

“…14,[16][17][18][19][20] Furthermore, reported discontinuation rates ranged from 0% to 9.8%, with the most frequent causes of treatment interruption represented by loss of efficacy, outbreak of PsA, arthromyalgia, injection site reaction, panic attack, eczema, and heart palpitation. 14,[16][17][18][19][20] Thus, our real-life experience may support that guselkumab is an effective and safe therapeutical option even in patients who failed ustekinumab and/or anti-IL-17 treatment.…”

Effectiveness and safety of guselkumab in 50 patients with moderate to severe plaque psoriasis who had previously been treated with other biologics: a retrospective real‐world evidence study

“…1 Guselkumab targets the cytokine IL-23 and shows very high efficacy but out-of-trial evidence is sparse. [2][3][4] We present real-world data from patients (n = 50) with moderate to severe plaque PsO who have consecutively initiated treatment with guselkumab at Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark, from April 2018 to October 2019 with registration of data until May 2020. Data were extracted from the electronic patient records and the prospective registry DERMBIO covering all patients with plaque PsO treated with biologics at departments of dermatology in Denmark.…”